According to the new market research report “Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) — Global Forecast”, published by MarketsandMarkets™.
The research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global viral inactivation market along with the estimates and forecasts of the revenue and market share analysis.
The Global Viral Inactivation Market is expected to reach $ 320.5 million, will grow at a CAGR of 12.3%
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121427017
Browse and in-depth TOC on “Viral Inactivation Market”
85 — Tables
41 — Figures
130 — Pages
Major Drivers For Viral Inactivation Market:
· Rapid Growth in Pharmaceutical and Biotechnology Industries
· Increasing Number of New Drug Launches
· Strong R&D Investments in the Life Sciences Industry
· Increasing Government Support for Pharmaceutical and Biotechnology Industries
· High Incidence and Large Economic Burden of Chronic Diseases
The global market is segmented based on method, product, application, end user, and geography.
Based on end-user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.
Request Research Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=121427017
Viral Inactivation Market By Application
- Blood & Blood Products
- Cellular & Gene Therapy Products
- Stem Cell Products
- Tissue & Tissue Products
- Vaccines and Therapeutics
The major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).
The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.
